Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial

Increasing the remission rate and reducing the recurrence rate can improve the clinical efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non-Hodgkin lymphoma (r/rNHL). In this open-label, single-arm phase I/II trial, 87 patients with r/rNHL, including 58 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yajing, Wang, Yao, Liu, Yang, Tong, Chuan, Wang, Chunmeng, Guo, Yelei, Ti, Dongdong, Yang, Qingming, Qiao, Shen, Wu, Zhiqiang, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727291/
https://www.ncbi.nlm.nih.gov/pubmed/34272481
http://dx.doi.org/10.1038/s41375-021-01345-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727291/
https://www.ncbi.nlm.nih.gov/pubmed/34272481
http://dx.doi.org/10.1038/s41375-021-01345-8

Ejemplares similares